- Reuters
Save time and jump to the most important pieces.
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)
3 - Lexaria Bioscience Corp. (0001348362) (Issuer)
3 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations."Mike is an accomplished individual who brings a wealth of financial and regulatory knowledge and experience to the table," said Richard Christopher, Chief Executive Officer of Lexaria. "On behalf of the entire Lexaria team, I'm thrilled to welcome Mike as our CFO as we continue to strengthen our executive tea
KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Cabatuan will lead the Company's financial operations."Nelson's deep financial leadership experience will be instrumental to the execution of Lexaria's long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs," said Chris Bunka, Chief Executive Officer
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants.Lexaria is pleased to announce that effective April 15, 2021, Gregory Downey will be assuming the role of Chief Financial Officer of the Company. During the past two years, Mr. Downey has been engaged by the Company as its Controller and has intimate knowledge regarding the Company's business and finances. Mr. Downey brings a wealth of experience to Lexaria, having served as the Chief
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study").Blood Sugar Levels (mmol/L)DehydraTECH GroupsDay 7 BaselineDay 28% Change to Day 28Day 56% Change to Day 56Day 84% Change to Day 84A: CBD127.426.2-4.31%26.9-1.90%27.71.09%B: CBD228.429.22.73%26.6-6.22%27.3-3.76%C: CBD326.424.9-5.99%27.12.46%27.53.85%D: CBD424.627.913.16%26.8
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all DehydraTECH groups KELOWNA, BC / ACCESSWIRE / October 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study").Animal Weights (grams)DehydraTECHGroupsEnd ofAcclimationPeriodDay28% Changeto Day28Day56%Changeto Day56Day84%Changeto Day84A: CBD1427.9432.6+1.10%438.0+2.36%43
KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW))) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon
8-K - Lexaria Bioscience Corp. (0001348362) (Filer)
8-K - Lexaria Bioscience Corp. (0001348362) (Filer)
D - Lexaria Bioscience Corp. (0001348362) (Filer)
HC Wainwright & Co. analyst Yi Chen reiterates Lexaria Bioscience (NASDAQ:LEXX) with a Buy and maintains $10 price target.
- Reuters
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces plans for strategic growth."Lexaria has certain initiatives underway that are increasing confidence in our medium-term and longer-term strategies," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "As a result of the success we are experiencing and the continued success we are anticipating, we will be implementing a number of strategic steps in the weeks and months to come."Lexaria will be expanding its management team this summer as it prepares for the greater workload of multiple projects and initiatives. The first step is appointin